Ambrisentan
Total Payments
$358,596
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $358,596 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $358,596 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Ambrisentan Fed Pivotal Study | West-Ward Pharmaceuticals | $188,108 | 0 |
| Ambrisentan Fasted Pivotal Study | West-Ward Pharmaceuticals | $170,487 | 0 |
Top Doctors Receiving Payments for Ambrisentan
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | — | $358,596 | 2 |
Ad
Manufacturing Companies
- West-Ward Pharmaceuticals $358,596
Product Information
- Type Drug
- Total Payments $358,596
- Total Doctors 0
- Transactions 2
About Ambrisentan
Ambrisentan is a drug associated with $358,596 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is West-Ward Pharmaceuticals.
Payment data is available from 2017 to 2017. In 2017, $358,596 was paid across 2 transactions to 0 doctors.
The most common payment nature for Ambrisentan is "Unspecified" ($358,596, 100.0% of total).
Ambrisentan is associated with 2 research studies, including "Ambrisentan Fed Pivotal Study" ($188,108).